341 related articles for article (PubMed ID: 33976188)
1. Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer.
Luo L; Zhang Z; Qiu N; Ling L; Jia X; Song Y; Li H; Li J; Lyu H; Liu H; He Z; Liu B; Zheng G
Nat Commun; 2021 May; 12(1):2699. PubMed ID: 33976188
[TBL] [Abstract][Full Text] [Related]
2. MiR-98-5p/IGF2 Axis Influence Herceptin Sensitivity through IGF1R/HER2 Heterodimer Formation and AKT/mTOR Signal Pathway in HER2 Positive Breast Cancer.
Zhang M; Li Z; Liu X
Asian Pac J Cancer Prev; 2021 Nov; 22(11):3693-3703. PubMed ID: 34837929
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
[TBL] [Abstract][Full Text] [Related]
4. FoxP3-miR-150-5p/3p suppresses ovarian tumorigenesis via an IGF1R/IRS1 pathway feedback loop.
Zhang Q; Zhou X; Wan M; Zeng X; Luo J; Xu Y; Ji L; Zhang JA; Fan P; Zhong J; Wu J
Cell Death Dis; 2021 Mar; 12(3):275. PubMed ID: 33723215
[TBL] [Abstract][Full Text] [Related]
5. miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer.
Guo J; Zhong X; Tan Q; Yang S; Liao J; Zhuge J; Hong Z; Deng Q; Zuo Q
Cell Death Dis; 2021 Jul; 12(7):696. PubMed ID: 34257270
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1.
Sanabria-Figueroa E; Donnelly SM; Foy KC; Buss MC; Castellino RC; Paplomata E; Taliaferro-Smith L; Kaumaya PT; Nahta R
Mol Pharmacol; 2015 Feb; 87(2):150-61. PubMed ID: 25391374
[TBL] [Abstract][Full Text] [Related]
7. IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling.
Oliva CR; Halloran B; Hjelmeland AB; Vazquez A; Bailey SM; Sarkaria JN; Griguer CE
Cell Commun Signal; 2018 Sep; 16(1):61. PubMed ID: 30231881
[TBL] [Abstract][Full Text] [Related]
8. A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1.
Xu Q; Jiang Y; Yin Y; Li Q; He J; Jing Y; Qi YT; Xu Q; Li W; Lu B; Peiper SS; Jiang BH; Liu LZ
J Mol Cell Biol; 2013 Feb; 5(1):3-13. PubMed ID: 22935141
[TBL] [Abstract][Full Text] [Related]
9. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.
Gijsen M; King P; Perera T; Parker PJ; Harris AL; Larijani B; Kong A
PLoS Biol; 2010 Dec; 8(12):e1000563. PubMed ID: 21203579
[TBL] [Abstract][Full Text] [Related]
10. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
Tovar V; Alsinet C; Villanueva A; Hoshida Y; Chiang DY; Solé M; Thung S; Moyano S; Toffanin S; Mínguez B; Cabellos L; Peix J; Schwartz M; Mazzaferro V; Bruix J; Llovet JM
J Hepatol; 2010 Apr; 52(4):550-9. PubMed ID: 20206398
[TBL] [Abstract][Full Text] [Related]
11. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
13. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
[TBL] [Abstract][Full Text] [Related]
14. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
[TBL] [Abstract][Full Text] [Related]
15. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.
Huang X; Gao L; Wang S; McManaman JL; Thor AD; Yang X; Esteva FJ; Liu B
Cancer Res; 2010 Feb; 70(3):1204-14. PubMed ID: 20103628
[TBL] [Abstract][Full Text] [Related]
16. FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling.
Shi Y; Ma Z; Cheng Q; Wu Y; Parris AB; Kong L; Yang X
Biochim Biophys Acta Mol Cell Res; 2021 Jan; 1868(1):118877. PubMed ID: 33007330
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS
PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685
[TBL] [Abstract][Full Text] [Related]
18. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2.
Yang M; Shan X; Zhou X; Qiu T; Zhu W; Ding Y; Shu Y; Liu P
Anticancer Agents Med Chem; 2014; 14(6):884-91. PubMed ID: 24875127
[TBL] [Abstract][Full Text] [Related]
19. miR-520b Inhibits IGF-1R to Increase Doxorubicin Sensitivity and Promote Cell Apoptosis in Breast Cancer.
Zhang H; Zheng XD; Zeng XH; Li L; Zhou Q
Yakugaku Zasshi; 2021 Mar; 141(3):415-426. PubMed ID: 33116033
[TBL] [Abstract][Full Text] [Related]
20. Decoding molecular interplay between RUNX1 and FOXO3a underlying the pulsatile IGF1R expression during acquirement of chemoresistance.
Dhadve AC; Hari K; Rekhi B; Jolly MK; De A; Ray P
Biochim Biophys Acta Mol Basis Dis; 2020 Jun; 1866(6):165754. PubMed ID: 32142859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
